Current Problems in Cardiology最新文献

英文中文

Knowledge mapping of SGLT2-inhibitors and cardiovascular outcomes: A bibliometric analysis sglt2抑制剂与心血管结局的知识图谱：文献计量学分析。

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-09-10 DOI: 10.1016/j.cpcardiol.2025.103171

Aysa Rezabakhsh , Hadis Iraji , Ashot Avagimyan , Elena Aghajanova , Zinaida Jndoyan , Lilia Mirzoyan , Waseem Hassan , Solomon Habtemariam , Anne Meddahi-Pellé , Graciela Pavon-Djavid , Abolfazl Barzegri

Introduction

Initially developed for the treatment of type 2 diabetes mellitus (T2DM), SGLT2 inhibitors have increasingly been recognized for their substantial cardiovascular, renal, and metabolic benefits. This study undertakes a systematic bibliometric analysis to delineate research trends, quantify advancements, and identify influential studies on SGLT2 inhibitors and cardiovascular outcomes.

Methods

A comprehensive literature search was performed using the Scopus database, resulting in 10,211 documents up to the search date. Both original research articles and reviews (narrative and systematic) were included. Quantitative metrics such as publication count, citation analysis, and authorship were employed. Network visualization tools (e.g., VOSviewer) and bibliometric software (R Studio with bibliometrix packages) were used to analyze collaboration networks, keyword co-occurrence, and thematic clustering.

Results

The analysis revealed a significant upward trend in publication volume, with a notable peak in recent years, indicating a heightened interest in the topic among scientists. The United States and selected European institutions emerged as major contributors, with prominent authors and funding sources influencing the research output. Thematic analysis highlighted a focus on cardiovascular diseases, heart failure, renal outcomes, and mechanistic studies of SGLT2 inhibitor action. Notably, landmark randomized controlled trials have reported significant reductions in cardiovascular mortality, heart failure hospitalizations, and progression of kidney disease.

Conclusion

This study underscores the transformative impact of SGLT2 inhibitors on cardiovascular therapy. The analytical framework highlights the expansion of the field, and the integration of translational research.

SGLT2抑制剂最初是为治疗2型糖尿病（T2DM）而开发的，现已越来越多地因其在心血管、肾脏和代谢方面的重大益处而得到认可。本研究进行了系统的文献计量分析，以描述研究趋势，量化进展，并确定SGLT2抑制剂和心血管结局的影响研究。方法：利用Scopus数据库进行全面的文献检索，截至检索日期共检索文献10211篇。包括原始研究文章和评论（叙述性和系统性）。定量指标，如发表数，引文分析和作者被采用。使用网络可视化工具（如VOSviewer）和文献计量软件（带有bibliometrix软件包的R Studio）分析协作网络、关键词共现和主题聚类。结果：分析显示，出版物数量呈显著上升趋势，近年来出现了一个显著的高峰，表明科学家对该主题的兴趣日益浓厚。美国和部分欧洲机构成为主要贡献者，其著名作者和资金来源影响着研究成果。专题分析强调了心血管疾病、心力衰竭、肾脏结局和SGLT2抑制剂作用机制研究的重点。值得注意的是，具有里程碑意义的随机对照试验报告了心血管死亡率、心力衰竭住院率和肾脏疾病进展的显著降低。结论：本研究强调了SGLT2抑制剂对心血管治疗的变革性影响。分析框架突出了领域的拓展，以及转化研究的整合。

{"title":"Knowledge mapping of SGLT2-inhibitors and cardiovascular outcomes: A bibliometric analysis","authors":"Aysa Rezabakhsh , Hadis Iraji , Ashot Avagimyan , Elena Aghajanova , Zinaida Jndoyan , Lilia Mirzoyan , Waseem Hassan , Solomon Habtemariam , Anne Meddahi-Pellé , Graciela Pavon-Djavid , Abolfazl Barzegri","doi":"10.1016/j.cpcardiol.2025.103171","DOIUrl":"10.1016/j.cpcardiol.2025.103171","url":null,"abstract":"<div><h3>Introduction</h3><div>Initially developed for the treatment of type 2 diabetes mellitus (T2DM), SGLT2 inhibitors have increasingly been recognized for their substantial cardiovascular, renal, and metabolic benefits. This study undertakes a systematic bibliometric analysis to delineate research trends, quantify advancements, and identify influential studies on SGLT2 inhibitors and cardiovascular outcomes.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was performed using the Scopus database, resulting in 10,211 documents up to the search date. Both original research articles and reviews (narrative and systematic) were included. Quantitative metrics such as publication count, citation analysis, and authorship were employed. Network visualization tools (e.g., VOSviewer) and bibliometric software (R Studio with bibliometrix packages) were used to analyze collaboration networks, keyword co-occurrence, and thematic clustering.</div></div><div><h3>Results</h3><div>The analysis revealed a significant upward trend in publication volume, with a notable peak in recent years, indicating a heightened interest in the topic among scientists. The United States and selected European institutions emerged as major contributors, with prominent authors and funding sources influencing the research output. Thematic analysis highlighted a focus on cardiovascular diseases, heart failure, renal outcomes, and mechanistic studies of SGLT2 inhibitor action. Notably, landmark randomized controlled trials have reported significant reductions in cardiovascular mortality, heart failure hospitalizations, and progression of kidney disease.</div></div><div><h3>Conclusion</h3><div>This study underscores the transformative impact of SGLT2 inhibitors on cardiovascular therapy. The analytical framework highlights the expansion of the field, and the integration of translational research.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 12","pages":"Article 103171"},"PeriodicalIF":3.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management 非酒精性脂肪肝、2型糖尿病和心血管疾病的三位一体关系：从分子机制到临床管理

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-09-03 DOI: 10.1016/j.cpcardiol.2025.103170

Yuxi Jin , Mohammed Alissa , Ahmed Ezzat Ahmed , Amin A. Al-Doaiss , Naif Asiri , Yasser Assiri , Shahid Ullah Khan Phd , Munir Ullah Khan , Samuel Joseph

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) represent interconnected metabolic disorders with multifaceted etiology, demonstrating bidirectional relationships and pronounced associations with cardiovascular diseases (CVDs). Despite extensive research, significant knowledge gaps persist regarding the temporal progression of these comorbidities, optimal screening strategies for high-risk populations, and personalized therapeutic approaches targeting the hepatic-cardiac-metabolic axis simultaneously. Current literature lacks a comprehensive analysis of phenotypic heterogeneity within NAFLD-T2DM-CVD clusters and fails to address sex-specific and ethnic variations in disease progression patterns adequately. A systematic literature search was conducted across PubMed, Medline, Embase, Web of Science, and Google Scholar databases from inception to June 2024, employing various combinations of terms including NAFLD, NASH, T2DM, and CVDs, with emphasis on identifying mechanistic pathways, epidemiological trends, and therapeutic innovations. This review identifies novel pathophysiological mechanisms linking hepatic steatosis, insulin resistance, and cardiovascular dysfunction, including previously underexplored roles of gut microbiome dysbiosis, advanced glycation end products, and epigenetic modifications. Emerging evidence suggests distinct molecular signatures that could facilitate precision medicine approaches. The intricate interplay between diabetes, hepatic dysfunction, and cardiovascular complications represents a global health challenge requiring integrated management strategies. Future research should prioritize developing biomarker-guided therapeutic algorithms, investigating sex-specific treatment responses, and establishing standardized protocols for concurrent NAFLD-T2DM-CVD management to optimize clinical outcomes and reduce healthcare burden.

非酒精性脂肪性肝病（NAFLD）和2型糖尿病（T2DM）是具有多方面病因的相互关联的代谢性疾病，与心血管疾病（cvd）表现出双向关系和明显的相关性。尽管进行了广泛的研究，但关于这些合并症的时间进展，高危人群的最佳筛查策略以及同时针对肝-心-代谢轴的个性化治疗方法，仍然存在重大的知识空白。目前的文献缺乏对NAFLD-T2DM-CVD集群表型异质性的全面分析，未能充分解决疾病进展模式的性别特异性和种族差异。系统地检索了PubMed、Medline、Embase、Web of Science和谷歌Scholar数据库，检索时间从成立到2024年6月，检索了包括NAFLD、NASH、T2DM和cvd在内的各种术语组合，重点是确定机制途径、流行病学趋势和治疗创新。本综述确定了与肝脂肪变性、胰岛素抵抗和心血管功能障碍相关的新的病理生理机制，包括以前未被充分探索的肠道微生物群失调、晚期糖基化终产物和表观遗传修饰的作用。新出现的证据表明，不同的分子特征可以促进精准医疗方法。糖尿病、肝功能障碍和心血管并发症之间错综复杂的相互作用是一项全球健康挑战，需要综合管理策略。未来的研究应优先开发生物标志物引导的治疗算法，调查性别特异性治疗反应，并建立NAFLD-T2DM-CVD并发管理的标准化方案，以优化临床结果并减轻医疗负担。

{"title":"The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management","authors":"Yuxi Jin , Mohammed Alissa , Ahmed Ezzat Ahmed , Amin A. Al-Doaiss , Naif Asiri , Yasser Assiri , Shahid Ullah Khan Phd , Munir Ullah Khan , Samuel Joseph","doi":"10.1016/j.cpcardiol.2025.103170","DOIUrl":"10.1016/j.cpcardiol.2025.103170","url":null,"abstract":"<div><div>Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) represent interconnected metabolic disorders with multifaceted etiology, demonstrating bidirectional relationships and pronounced associations with cardiovascular diseases (CVDs). Despite extensive research, significant knowledge gaps persist regarding the temporal progression of these comorbidities, optimal screening strategies for high-risk populations, and personalized therapeutic approaches targeting the hepatic-cardiac-metabolic axis simultaneously. Current literature lacks a comprehensive analysis of phenotypic heterogeneity within NAFLD-T2DM-CVD clusters and fails to address sex-specific and ethnic variations in disease progression patterns adequately. A systematic literature search was conducted across PubMed, Medline, Embase, Web of Science, and Google Scholar databases from inception to June 2024, employing various combinations of terms including NAFLD, NASH, T2DM, and CVDs, with emphasis on identifying mechanistic pathways, epidemiological trends, and therapeutic innovations. This review identifies novel pathophysiological mechanisms linking hepatic steatosis, insulin resistance, and cardiovascular dysfunction, including previously underexplored roles of gut microbiome dysbiosis, advanced glycation end products, and epigenetic modifications. Emerging evidence suggests distinct molecular signatures that could facilitate precision medicine approaches. The intricate interplay between diabetes, hepatic dysfunction, and cardiovascular complications represents a global health challenge requiring integrated management strategies. Future research should prioritize developing biomarker-guided therapeutic algorithms, investigating sex-specific treatment responses, and establishing standardized protocols for concurrent NAFLD-T2DM-CVD management to optimize clinical outcomes and reduce healthcare burden.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103170"},"PeriodicalIF":3.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2-targeted therapies and cardiotoxicity: From major concern to manageable risk her2靶向治疗和心脏毒性：从主要关注到可控风险。

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-09-03 DOI: 10.1016/j.cpcardiol.2025.103168

Rio Putra Pamungkas MD , Laras Pratiwi MD , Henry Sutanto MD, MSc, PhD

HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, but their potential for cardiotoxicity remains a critical clinical concern. Early trials reported high rates of cardiac dysfunction, particularly with concomitant anthracycline use, prompting the development of intensive cardiac monitoring strategies. However, emerging evidence suggests that most cardiotoxic events are asymptomatic, reversible, and rarely require permanent treatment discontinuation, particularly with newer agents such as antibody–drug conjugates. Clinical determinants include baseline left ventricular dysfunction, age, comorbidities, and combination chemotherapy, while biomarkers and advanced imaging are promising tools for early detection. Mechanistically, HER2 inhibition disrupts cardiomyocyte survival pathways and mitochondrial function, but the relationship between these changes and clinically meaningful heart failure remains incompletely defined. Recent studies, including SAFE-HEaRt, demonstrate that HER2 therapy can often be safely continued under cardio-oncology supervision with appropriate cardioprotective interventions. Nevertheless, gaps persist in risk stratification, long-term surveillance, and the integration of biomarkers and imaging into routine practice. This article critically examines the pathophysiology, clinical risk factors, and management of HER2 therapy-induced cardiotoxicity, ultimately arguing that with proper monitoring and multidisciplinary care, cardiotoxicity should not preclude optimal oncologic treatment.

her2靶向治疗显著改善了her2阳性乳腺癌患者的预后，但其潜在的心脏毒性仍然是一个关键的临床问题。早期的试验报告了心功能障碍的高发率，特别是与蒽环类药物的同时使用，促使了强化心脏监测策略的发展。然而，新出现的证据表明，大多数心脏毒性事件是无症状的，可逆的，很少需要永久停止治疗，特别是使用新的药物，如抗体-药物偶联物。临床决定因素包括基线左心室功能障碍、年龄、合并症和联合化疗，而生物标志物和先进的成像是早期发现的有希望的工具。从机制上讲，HER2抑制会破坏心肌细胞存活途径和线粒体功能，但这些变化与临床意义上的心力衰竭之间的关系仍不完全明确。包括SAFE-HEaRt在内的近期研究表明，在心脏肿瘤学监督下，适当的心脏保护干预措施通常可以安全地继续进行HER2治疗。然而，在风险分层、长期监测以及将生物标志物和成像纳入常规实践方面仍然存在差距。本文严格检查了HER2治疗诱导的心脏毒性的病理生理学、临床危险因素和管理，最终认为通过适当的监测和多学科护理，心脏毒性不应排除最佳的肿瘤治疗。

{"title":"HER2-targeted therapies and cardiotoxicity: From major concern to manageable risk","authors":"Rio Putra Pamungkas MD , Laras Pratiwi MD , Henry Sutanto MD, MSc, PhD","doi":"10.1016/j.cpcardiol.2025.103168","DOIUrl":"10.1016/j.cpcardiol.2025.103168","url":null,"abstract":"<div><div>HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, but their potential for cardiotoxicity remains a critical clinical concern. Early trials reported high rates of cardiac dysfunction, particularly with concomitant anthracycline use, prompting the development of intensive cardiac monitoring strategies. However, emerging evidence suggests that most cardiotoxic events are asymptomatic, reversible, and rarely require permanent treatment discontinuation, particularly with newer agents such as antibody–drug conjugates. Clinical determinants include baseline left ventricular dysfunction, age, comorbidities, and combination chemotherapy, while biomarkers and advanced imaging are promising tools for early detection. Mechanistically, HER2 inhibition disrupts cardiomyocyte survival pathways and mitochondrial function, but the relationship between these changes and clinically meaningful heart failure remains incompletely defined. Recent studies, including SAFE-HEaRt, demonstrate that HER2 therapy can often be safely continued under cardio-oncology supervision with appropriate cardioprotective interventions. Nevertheless, gaps persist in risk stratification, long-term surveillance, and the integration of biomarkers and imaging into routine practice. This article critically examines the pathophysiology, clinical risk factors, and management of HER2 therapy-induced cardiotoxicity, ultimately arguing that with proper monitoring and multidisciplinary care, cardiotoxicity should not preclude optimal oncologic treatment.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103168"},"PeriodicalIF":3.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of 0.5 mg dose of colchicine on clinical outcomes in patients with acute myocardial infarction: An updated meta-analysis of randomized controlled trials 0.5 mg秋水仙碱对急性心肌梗死患者临床结局的影响：一项随机对照试验的最新荟萃分析

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-09-03 DOI: 10.1016/j.cpcardiol.2025.103169

Ahmed Nazmy MD , Ahmed Sobhy MD , Ahmed Elshahat MD , Karim Atta MD , Mohamed R. Murad MD , Moustafa Ibrahim MD , Hassan El-Shirbiny MD , Rahma Abdelfattah Ibrahim MD , Mohamed Saad Sayed MD , Mahmoud Gomaa MD , Ahmed Yasser Shaban MD , Mohamed Naeem MD , Ahmed Abdelaziz MD

Background

Inflammation plays a critical role in the progression of atherosclerosis, and the anti-inflammatory effects on clinical outcomes of patients with acute myocardial infarction (AMI) are still uncertain.

Objectives

We aimed to study the effects of a 0.5 mg dose of colchicine on clinical outcomes following AMI.

Methods

We systematically searched PubMed, Scopus, Web of Science, and Cochrane Central from inception to January 2025 for randomized controlled trials (RCTs) assessing 0.5 mg colchicine in AMI patients. The primary outcome was the incidence of major adverse cardiovascular events (MACE). Secondary outcomes included individual MACE components, cardiovascular (CV) and non-CV mortality, atrial fibrillation (AF), hospital readmission, and gastrointestinal (GIT) adverse events, including diarrhea.

Results

Ten RCTs involving 13,623 patients with a median follow-up of 6 months (range 5 days–36 months) were included. Low-dose colchicine showed a non-significant trend toward reducing MACE versus placebo (RR = 0.90, 95% CI: 0.80–1.01, p = 0.07; I² = 0%). Hospital readmission was significantly reduced by 49% (OR = 0.51, 95% CI: 0.26–0.98, p = 0.04; number needed to treat [NNT] = 25). Colchicine increased the risk of diarrhea (RR = 1.58, 95% CI: 1.06–2.36, p = 0.03; I² = 71%; number needed to harm [NNH] = 50) but showed no significant differences in all-cause mortality, CV mortality, myocardial infarction, stroke, or other GIT events.

Conclusion

Low-dose colchicine had a lower hospital readmission rate, but with higher rates of diarrhea compared to placebo. Long-term assessment is indeed to validate the current findings.

背景：炎症在动脉粥样硬化的进展中起着至关重要的作用，抗炎对急性心肌梗死（AMI）患者临床结局的影响尚不确定。目的：研究0.5 mg秋水仙碱对急性心肌梗死后临床预后的影响。方法：我们系统地检索PubMed、Scopus、Web of Science和Cochrane Central从成立到2025年1月的随机对照试验（rct），评估0.5 mg秋水仙碱对AMI患者的影响。主要终点是主要不良心血管事件（MACE）的发生率。次要结局包括个体MACE成分、心血管（CV）和非CV死亡率、心房颤动（AF）、再入院和胃肠道（GIT）不良事件，包括腹泻。结果：纳入10项随机对照试验，涉及13,623例患者，中位随访时间为6个月（5天-36个月）。与安慰剂相比，低剂量秋水仙碱降低MACE的趋势不显著（RR = 0.90,95% CI: 0.80-1.01, p = 0.07;I² = 0%）。再入院率显著降低49% （OR = 0.51,95% CI: 0.26-0.98, p = 0.04；所需治疗人数[NNT] = 25）。秋水仙碱增加了腹泻的风险（RR = 1.58,95% CI: 1.06-2.36, p = 0.03;I² = 71%；所需伤害数[NNH] = 50），但在全因死亡率、CV死亡率、心肌梗死、卒中或其他GIT事件方面无显著差异。结论：与安慰剂相比，低剂量秋水仙碱的再入院率较低，但腹泻率较高。长期评估确实验证了目前的发现。

{"title":"The effect of 0.5 mg dose of colchicine on clinical outcomes in patients with acute myocardial infarction: An updated meta-analysis of randomized controlled trials","authors":"Ahmed Nazmy MD , Ahmed Sobhy MD , Ahmed Elshahat MD , Karim Atta MD , Mohamed R. Murad MD , Moustafa Ibrahim MD , Hassan El-Shirbiny MD , Rahma Abdelfattah Ibrahim MD , Mohamed Saad Sayed MD , Mahmoud Gomaa MD , Ahmed Yasser Shaban MD , Mohamed Naeem MD , Ahmed Abdelaziz MD","doi":"10.1016/j.cpcardiol.2025.103169","DOIUrl":"10.1016/j.cpcardiol.2025.103169","url":null,"abstract":"<div><h3>Background</h3><div>Inflammation plays a critical role in the progression of atherosclerosis, and the anti-inflammatory effects on clinical outcomes of patients with acute myocardial infarction (AMI) are still uncertain.</div></div><div><h3>Objectives</h3><div>We aimed to study the effects of a 0.5 mg dose of colchicine on clinical outcomes following AMI.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Scopus, Web of Science, and Cochrane Central from inception to January 2025 for randomized controlled trials (RCTs) assessing 0.5 mg colchicine in AMI patients. The primary outcome was the incidence of major adverse cardiovascular events (MACE). Secondary outcomes included individual MACE components, cardiovascular (CV) and non-CV mortality, atrial fibrillation (AF), hospital readmission, and gastrointestinal (GIT) adverse events, including diarrhea.</div></div><div><h3>Results</h3><div>Ten RCTs involving 13,623 patients with a median follow-up of 6 months (range 5 days–36 months) were included. Low-dose colchicine showed a non-significant trend toward reducing MACE versus placebo (RR = 0.90, 95% CI: 0.80–1.01, p = 0.07; I² = 0%). Hospital readmission was significantly reduced by 49% (OR = 0.51, 95% CI: 0.26–0.98, p = 0.04; number needed to treat [NNT] = 25). Colchicine increased the risk of diarrhea (RR = 1.58, 95% CI: 1.06–2.36, p = 0.03; I² = 71%; number needed to harm [NNH] = 50) but showed no significant differences in all-cause mortality, CV mortality, myocardial infarction, stroke, or other GIT events.</div></div><div><h3>Conclusion</h3><div>Low-dose colchicine had a lower hospital readmission rate, but with higher rates of diarrhea compared to placebo. Long-term assessment is indeed to validate the current findings.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103169"},"PeriodicalIF":3.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editor’s Message 编辑器’的消息

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-09-02 DOI: 10.1016/S0146-2806(25)00179-3

引用次数: 0

Guidelines for Authors 作者指南

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-09-02 DOI: 10.1016/S0146-2806(25)00182-3

引用次数: 0

Information for Readers 读者资讯

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-09-02 DOI: 10.1016/S0146-2806(25)00181-1

引用次数: 0

Title Page 标题页

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-09-02 DOI: 10.1016/S0146-2806(25)00178-1

引用次数: 0

The top 100 most cited articles in cardiovascular research: A bibliometric perspective 心血管研究中被引用最多的100篇文章：文献计量学视角

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-08-25 DOI: 10.1016/j.cpcardiol.2025.103153

Siddig Ibrahim Abdelwahab , Manal Mohamed Elhassan Taha , Abdullah Farasani , Jobran M Moshi , Ahmad Assiri , Saeed Alshahrani , Khaled A Sahli , Hussam M. Shubaily , Waseem Hassan

Objective

The aim is to analyze the citation dynamics, and research focus of the top 100 most cited cardiovascular research.

Methods

Data were retrieved from the Scopus database in January 2025, focusing on journals containing the term “cardio” in their title. Only original research articles and reviews were included. The data were analyzed using VOSviewer and R Studio to assess co-authorship networks, keyword co-occurrence, citation mapping, and citation impact indicators.

Results

A total of 100 articles, published between 1967 and 2020, were included in the analysis. These articles had an average of 2,285 citations each. The growth rate of publications was 3.74 %, with an average document age of 20.8 years. Collaboration was extensive, with 1,653 authors contributing to these papers, and 25 % of publications involved international collaboration. Citation analysis showed increasing citation rates over time, with recent papers achieving significant impact in a short period. The top authors, universities, countries, and sources of publication were identified, revealing the global nature of cardiovascular research and its collaborative nature. The title co-words analysis was also performed to understand the main focus of the most cited papers.

Conclusions

This study offers a deeper understanding of the most cited cardiovascular research papers, addressing gaps in previous bibliometric studies by providing insights into citation dynamics, author collaborations, and thematic shifts. Future studies should explore the quality of research and expand the scope of bibliometric analyses.

目的分析被引频次前100位的心血管科学研究的被引动态及研究热点。方法于2025年1月从Scopus数据库中检索，重点检索标题中包含cardio一词的期刊。仅纳入原创研究文章和综述。使用VOSviewer和R Studio对数据进行分析，评估合著网络、关键词共现、引文映射和引文影响指标。结果共纳入1967 - 2020年间发表的100篇文献。这些文章平均每篇被引用2285次。发文量增长率为3.74%，平均文献年龄为20.8年。合作非常广泛，有1653位作者对这些论文做出了贡献，25%的出版物涉及国际合作。引文分析显示，随着时间的推移，被引率呈上升趋势，近期论文在短时间内产生显著影响。确定了顶级作者、大学、国家和出版物来源，揭示了心血管研究的全球性质及其合作性质。还进行了标题共词分析，以了解被引次数最多的论文的主要焦点。本研究提供了对被引用最多的心血管研究论文的更深入了解，通过提供对引用动态、作者合作和主题变化的见解，解决了以前文献计量学研究中的空白。未来的研究应探索研究的质量，并扩大文献计量分析的范围。

{"title":"The top 100 most cited articles in cardiovascular research: A bibliometric perspective","authors":"Siddig Ibrahim Abdelwahab , Manal Mohamed Elhassan Taha , Abdullah Farasani , Jobran M Moshi , Ahmad Assiri , Saeed Alshahrani , Khaled A Sahli , Hussam M. Shubaily , Waseem Hassan","doi":"10.1016/j.cpcardiol.2025.103153","DOIUrl":"10.1016/j.cpcardiol.2025.103153","url":null,"abstract":"<div><h3>Objective</h3><div>The aim is to analyze the citation dynamics, and research focus of the top 100 most cited cardiovascular research.</div></div><div><h3>Methods</h3><div>Data were retrieved from the Scopus database in January 2025, focusing on journals containing the term “cardio” in their title. Only original research articles and reviews were included. The data were analyzed using VOSviewer and R Studio to assess co-authorship networks, keyword co-occurrence, citation mapping, and citation impact indicators.</div></div><div><h3>Results</h3><div>A total of 100 articles, published between 1967 and 2020, were included in the analysis. These articles had an average of 2,285 citations each. The growth rate of publications was 3.74 %, with an average document age of 20.8 years. Collaboration was extensive, with 1,653 authors contributing to these papers, and 25 % of publications involved international collaboration. Citation analysis showed increasing citation rates over time, with recent papers achieving significant impact in a short period. The top authors, universities, countries, and sources of publication were identified, revealing the global nature of cardiovascular research and its collaborative nature. The title co-words analysis was also performed to understand the main focus of the most cited papers.</div></div><div><h3>Conclusions</h3><div>This study offers a deeper understanding of the most cited cardiovascular research papers, addressing gaps in previous bibliometric studies by providing insights into citation dynamics, author collaborations, and thematic shifts. Future studies should explore the quality of research and expand the scope of bibliometric analyses.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103153"},"PeriodicalIF":3.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in cardiovascular risk in Peru: A 10-year population-based analysis (2015–2024) 秘鲁心血管风险趋势：基于人群的10年分析（2015-2024）

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology

Pub Date : 2025-08-20 DOI: 10.1016/j.cpcardiol.2025.103155

Carlos Diaz-Arocutipa MD , Natalia Nombera-Aznaran MD , Vicente Benites-Zapata MD , Pedro Kikushima-Alcantara MD , Percy Herrera-Añazco MD

Background

Data on national trends in cardiovascular risk in Latin America are limited. We aimed to evaluate changes in estimated 10-year cardiovascular risk in Peru between 2015 and 2024, and assess disparities by sex, age, residence, and region.

Methods

We conducted a cross-sectional analysis using nationally representative data from the Peruvian Demographic and Health Survey. Adults aged 40–74 years with complete risk factor data were included. Ten-year cardiovascular risk was estimated using the 2019 WHO non-laboratory prediction charts for Andean Latin America. Trends in mean absolute risk and the proportion of individuals at ≥high risk were assessed using joinpoint regression models, overall and by sex, age group, area of residence, and region.

Results

Among 104,617 participants, mean estimated 10-year cardiovascular risk declined from 5% in 2015 to 4.4% in 2024 (average annual percent change [AAPC] −2.3%; 95% C: −3.2 to −1.5). The prevalence of ≥high cardiovascular risk decreased from 10.3% to 8.5% (AAPC −3.2%; 95% CI −5.0 to −1.6). Risk declined significantly among women, younger adults, and both urban and rural populations, but remained unchanged in men and older adults. Regional trends were heterogeneous, with the steepest reductions observed in Amazonas, Ica, and Ayacucho.

Conclusions

Although a slight decline in estimated cardiovascular risk was observed in Peru over the past decade, the change may have limited clinical relevance. These trends emphasize the need for stronger, equity-focused efforts to reduce the burden of cardiovascular disease at the national level.

背景：关于拉丁美洲国家心血管风险趋势的数据有限。我们的目的是评估秘鲁2015年至2024年间10年心血管风险的变化，并评估性别、年龄、居住地和地区的差异。方法采用秘鲁人口与健康调查中具有全国代表性的数据进行横断面分析。年龄在40-74岁之间且有完整危险因素数据的成年人被纳入研究对象。使用2019年世卫组织安第斯拉丁美洲非实验室预测图估计了十年心血管风险。使用联合点回归模型评估总体和按性别、年龄组、居住区域和地区划分的平均绝对风险趋势和≥高风险个体比例。在104,617名参与者中，平均估计10年心血管风险从2015年的5%下降到2024年的4.4%（平均年变化百分比[AAPC] - 2.3%; 95% C: - 3.2至- 1.5）。≥高心血管风险的患病率从10.3%降至8.5% （AAPC为- 3.2%；95% CI为- 5.0至- 1.6）。风险在女性、年轻人以及城市和农村人口中显著下降，但在男性和老年人中保持不变。区域趋势是不均匀的，亚马逊、伊卡和阿亚库乔地区的降幅最大。结论：尽管秘鲁在过去十年中观察到心血管风险估计值略有下降，但这种变化可能具有有限的临床相关性。这些趋势强调需要加强以公平为重点的努力，在国家一级减轻心血管疾病负担。

{"title":"Trends in cardiovascular risk in Peru: A 10-year population-based analysis (2015–2024)","authors":"Carlos Diaz-Arocutipa MD , Natalia Nombera-Aznaran MD , Vicente Benites-Zapata MD , Pedro Kikushima-Alcantara MD , Percy Herrera-Añazco MD","doi":"10.1016/j.cpcardiol.2025.103155","DOIUrl":"10.1016/j.cpcardiol.2025.103155","url":null,"abstract":"<div><h3>Background</h3><div>Data on national trends in cardiovascular risk in Latin America are limited. We aimed to evaluate changes in estimated 10-year cardiovascular risk in Peru between 2015 and 2024, and assess disparities by sex, age, residence, and region.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional analysis using nationally representative data from the Peruvian Demographic and Health Survey. Adults aged 40–74 years with complete risk factor data were included. Ten-year cardiovascular risk was estimated using the 2019 WHO non-laboratory prediction charts for Andean Latin America. Trends in mean absolute risk and the proportion of individuals at ≥high risk were assessed using joinpoint regression models, overall and by sex, age group, area of residence, and region.</div></div><div><h3>Results</h3><div>Among 104,617 participants, mean estimated 10-year cardiovascular risk declined from 5% in 2015 to 4.4% in 2024 (average annual percent change [AAPC] −2.3%; 95% C: −3.2 to −1.5). The prevalence of ≥high cardiovascular risk decreased from 10.3% to 8.5% (AAPC −3.2%; 95% CI −5.0 to −1.6). Risk declined significantly among women, younger adults, and both urban and rural populations, but remained unchanged in men and older adults. Regional trends were heterogeneous, with the steepest reductions observed in Amazonas, Ica, and Ayacucho.</div></div><div><h3>Conclusions</h3><div>Although a slight decline in estimated cardiovascular risk was observed in Peru over the past decade, the change may have limited clinical relevance. These trends emphasize the need for stronger, equity-focused efforts to reduce the burden of cardiovascular disease at the national level.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 10","pages":"Article 103155"},"PeriodicalIF":3.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144891900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Current Problems in Cardiology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀